PanCareSurPass Project HL7 FHIR Implementation Guide
0.1.0 - trial-use 150

This page is part of the PanCareSurPass Project HL7 FHIR Implementation Guide (v0.1.0: QA Preview) based on FHIR R4. This is the current published version. For a full list of available versions, see the Directory of published versions

Table of Contents

...0 Table of Contents
...1 PanCareSurPass FHIR IG - Home Page
...2 PCSP Maturity Model
...3 Logical Models
...4 Sequence diagrams
...5 Collaboration diagrams
...6 Profiles
...7 Terminology
...8 Extensions
...9 Examples
...10 Useful Downloads
...11 IG Change History
....12 Artifacts Summary
....12.1 Chemotherapy
....12.2 Diagnosis
....12.3 Metadata FSE Italy
....12.4 Front Line Treatment
....12.5 Major Surgery
....12.6 Other info and relevant events
....12.7 Care Plan
....12.8 Radiotherapy
....12.9 Progression-Relapse after FLT
....12.10 Progression-Relapse during FLT
....12.11 Stem Cell Transplantation
....12.12 Subject of care
....12.13 SurPass V2.0
....12.14 Treatment Summary
....12.15 BiologicallyDerivedProduct: Stem Cell
....12.16 Bundle: Survivor Passport
....12.17 Observation: Cancer Stage Group
....12.18 CarePlan: PCSP-generated plan
....12.19 Composition: Survivor Passport
....12.20 Condition: GvHD
....12.21 Condition: Others
....12.22 Condition: Primary Cancer
....12.23 Condition: Metastatic Cancer
....12.24 Condition: Severe Toxicity
....12.25 Observation: Chemotherapy Cumulative Dose
....12.26 DocumentReference: PCSP
....12.27 Encounter: Treatment Center
....12.28 Location: PCSP
....12.29 MedicationAdministration: Chemotherapy
....12.30 MedicationStatement: Chemotherapy
....12.31 Observation: Blood type/RH
....12.32 Observation: Diagnosis details
....12.33 Observation: Hereditary Predisposition
....12.34 Observation: Risk Factor
....12.35 Organization: Primary Treatment Center / Center of diagnosis
....12.36 Patient: PCSP
....12.37 PlanDefinition: Front Line Treatment
....12.38 Procedure: Catheter
....12.39 Procedure: Cryopreservation
....12.40 Procedure: Front Line Treatment
....12.41 Procedure: Other Treatments
....12.42 Procedure: Radiotherapy Boost
....12.43 Procedure: Radiotherapy
....12.44 Procedure: Radiotherapy Shielding
....12.45 Procedure: Stem Cell Transplantation
....12.46 Procedure: SCT Prophylaxis
....12.47 Procedure: Surgery
....12.48 Procedure: Transfusion other infos
....12.49 Observation: TNM Distant Metastases Category
....12.50 Observation: TNM Primary Tumor Category
....12.51 Observation: TNM Regional Nodes Category
....12.52 Observation: Radiotherapy Total Dose PCSP
....12.53 Annotation Type
....12.54 Body Location Qualifier
....12.55 Condition related to resource
....12.56 Act Location
....12.57 Randomization arm for trial
....12.58 Laterality Qualifier
....12.59 Performed Timing
....12.60 Previous Status
....12.61 Procedure Used Reference
....12.62 Radiotherapy Energy or Isotope
....12.63 Relapse Type
....12.64 Resource related information
....12.65 Sacrified organ
....12.66 Stem Cell Donor Type
....12.67 Stem Cell Source Type
....12.68 Active or resolved Condition
....12.69 Affected Organs (surgery)
....12.70 Amputation Surgical Procedure Type
....12.71 Annotation type
....12.72 Body Location Qualifier Value Set
....12.73 Brachytherapy Type
....12.74 Calculated|Estimated
....12.75 Stage Group Value Set
....12.76 Cancer Staging System Value Set
....12.77 Chemotherapy cumulative dose units
....12.78 Colostomy Surgical Procedure Type
....12.79 Document Type
....12.80 FLT Plan Type
....12.81 Body Location Qualifier Value Set
....12.82 Gastrostomy Surgical Procedure Type
....12.83 Hereditary Predispositions or Disease
....12.84 ICCC-3
....12.85 Hereditary Predispositions (ICD10)
....12.86 ICD-O-3 Morphology
....12.87 ICD-O-3 Topography
....12.88 Laterality Qualifier Value Set
....12.89 Not Applicable|Unknown
....12.90 Not Performed|Unknown
....12.91 Observation Codes for Distant Metastases Category
....12.92 Observation Codes for Primary Tumor Category
....12.93 Observation Codes for Regional Node Category
....12.94 Observation Codes for Stage Group Category
....12.95 Hereditary Predispositions (Orphacode)
....12.96 Other Infors Condition
....12.97 Other/Unknown/Text
....12.98 Prosthesis Type
....12.99 Prosthetic Surgical Procedure Type
....12.100 Radiotherapy dose units
....12.101 Radiotherapy Device Type
....12.102 Radiotherapy Dose Type
....12.103 Radiotherapy Isotopes
....12.104 Radiotherapy Type
....12.105 Recommendations
....12.106 Relapse type (Local/Distant/Combined)
....12.107 Conditions at risk
....12.108 Risk Factors
....12.109 Route of administration
....12.110 Sacrified Organs (surgery)
....12.111 Acute Gvhd Grade
....12.112 Chronic Gvhd condition
....12.113 Stem Cell Donor type
....12.114 Gvhd condition
....12.115 SCT Prophylaxis Cathegory
....12.116 SCT Prophylaxis Type
....12.117 Stem Cell Source type
....12.118 Before/after procedure
....12.119 Stem Cell Transplantation type
....12.120 Shunt Procedure Type
....12.121 Surgical Actions
....12.122 Surgical Procedure Type
....12.123 TNM Distant Metastases Category Value Set
....12.124 TNM Primary Tumor Category Value Set
....12.125 TNM Regional Nodes Category Value Set
....12.126 Toxicity Severity
....12.127 Unknown|Other
....12.128 Antineoplastic and immunostimulating agents
....12.129 Radiotherapy sites
....12.130 PCSP Code System
....12.131 PCSP Recommendations
....12.132 PCSP Conditions at risk
....12.133 Risk Factors
....12.134 cs-radiotherapy-pcsp
....12.135 BiologicallyDerivedProduct: Stem Cell Transplantation
....12.136 CarePlan: Automatically Generated Example
....12.137 MedicationAdministration: Chemotherapy Hulafe Ciclofosfamide
....12.138 Observation: Chemotherapy Hulafe Ciclofosfamide Cumulative Dose
....12.139 MedicationAdministration: Chemotherapy Hulafe Citarabina
....12.140 Observation: Chemotherapy Hulafe Citarabina Cumulative Dose
....12.141 Location: Chemotherapy Hulafe
....12.142 MedicationAdministration: Chemotherapy Hulafe Metotrexato
....12.143 Observation: Chemotherapy Hulafe Metotrexato Cumulative Dose
....12.144 MedicationAdministration: Chemotherapy Hulafe Vincristina
....12.145 Observation: Chemotherapy Hulafe Vincristina Cumulative Dose
....12.146 MedicationStatement: Chemotherapy Hulafe Corticosteroids
....12.147 Condition: Sample from Mainz
....12.148 Condition: complete Primary Cancer Condition example (TBC)
....12.149 Condition: complete metastatic site Condition example (TBC)
....12.150 DocumentReference: Preliminary SurPass
....12.151 Encounter: Primary Diagnosis Hulafe (Encounter)
....12.152 Encounter: Sample from Mainz
....12.153 Encounter: Sample from Mainz (Zeisig)
....12.154 Location: Stem Cell Transplantation
....12.155 Observation: Blood type/RH before the SCT
....12.156 Observation: Sample from Mainz (Zeisig)
....12.157 Observation: Radiotherapy Total Dose
....12.158 Observation: Risk Factor
....12.159 Observation: Risk Factor
....12.160 Observation: Risk Factor
....12.161 Observation: Risk Factor
....12.162 Organization: Primary Diagnosis Hulafe (Organization)
....12.163 Patient: Sample from Cineca
....12.164 Patient: Sample from Hulafe
....12.165 Patient: Hulafe
....12.166 Patient: Sample created on Mainz data (Fischer)
....12.167 Patient: Sample created on Mainz data (Zeisig)
....12.168 Patient: Sample created on Vulsk data
....12.169 Condition: Primary Diagnosis Hulafe
....12.170 Procedure: Radiotherapy
....12.171 Procedure: Stem Cell Transplantation
....12.172 Procedure: Transfusion